# US 2025/0367138 A1 · Compositions, systems, and methods for treating cancer using tumor treating fields (ttfields) and methylglyoxal

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367138 A1
- Document ID: US20250367138A1
- Status: Published application
- Kind: A1
- Application number: 19/207,527
- Filed: 2025-05-14
- Published: 2025-12-04
- Earliest claimed: 2024-05-31
- Assignees: Novocure GmbH
- Applicants: Novocure GmbH
- Inventors: Maximilian SCHEER
- Web page: https://patentgrep.com/patent/US20250367138A1

## CPC

- A61K 31/11: Aldehydes
- A61K 31/121: acyclic
- A61N 1/36002: {Cancer treatment, e.g. tumour}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions, systems, and methods for reducing viability of cancer cells and treating cancer, as well as preventing an increase of volume of a tumor present in a body of a living subject, are disclosed. Also disclosed are methods of enhancing cytotoxicity of MGO against cancer cells. The systems and methods involve application of an alternating field in combination with administration of at least one composition comprising methylglyoxal (MGO).

## Claims

### Claim 1

A method of reducing viability of cancer cells, the method comprising the steps of:
(1) administering at least one composition to the cancer cells, wherein the at least one composition comprises methylglyoxal (MGO); and
(2) applying an alternating electric field to the cancer cells for a period of time.

### Claim 2 (depends on 1)

The method of claim 1, wherein at least one of:
the alternating electric field is applied at a frequency in a range of from about 50 kHz to about 1 MHz;
the alternating electric field has a field strength of at least about 1 V/cm in at least a portion of the cancer cells; and
the period of time that the alternating electric field is applied is at least about 50% of a 24 consecutive hour time period.

### Claim 3 (depends on 1)

The method of claim 1, wherein the at least one composition comprises methylglyoxal at a concentration in a range of from about 0.3 mM to about 1 mM.

### Claim 4 (depends on 1)

The method of claim 1, wherein steps (1) and (2) are performed substantially simultaneously.

### Claim 5 (depends on 1)

The method of claim 1, wherein steps (1) and (2) are performed wholly or partially sequentially.

### Claim 6 (depends on 1)

The method of claim 1, wherein steps (1) and (2) are repeated one or more times.

### Claim 7 (depends on 1)

The method of claim 1, wherein the cancer cells are selected from the group consisting of hepatocellular carcinoma cells, glioblastoma cells, pleural mesothelioma cells, differentiated thyroid cancer cells, advanced renal cell carcinoma cells, ovarian cancer cells, breast cancer cells, pancreatic cancer cells, lung cancer cells, colorectal cancer cells, and combinations thereof.

### Claim 8 (depends on 7)

The method of claim 7, wherein the cancer cells are glioblastoma cells.

### Claim 9

A method of treating cancer in a subject, the method comprising the steps of:
(1) administering at least one composition to the subject, wherein the at least one composition comprises methylglyoxal (MGO); and
(2) applying an alternating electric field to a target region of the subject.

### Claim 10 (depends on 9)

The method of claim 9, wherein the methylglyoxal is administered to the patient at a concentration in a range of from about 0.3 mM to about 1 mM.

### Claim 11 (depends on 9)

The method of claim 9, wherein the at least one composition is orally or intravenously administered to the subject.

### Claim 12 (depends on 9)

The method of claim 9, wherein at least one of:
the alternating electric field is applied at a frequency in a range of from about 50 kHz to about 1 MHz;
the alternating electric field has a field strength of at least about 1 V/cm in at least a portion of the target region; and
the period of time that the alternating electric field is applied is at least about 50% of a 24 consecutive hour time period.

### Claim 13 (depends on 9)

The method of claim 9, wherein steps (1) and (2) are performed substantially simultaneously.

### Claim 14 (depends on 9)

The method of claim 9, wherein steps (1) and (2) are performed wholly or partially sequentially.

### Claim 15 (depends on 9)

The method of claim 9, wherein steps (1) and (2) are repeated one or more times.

### Claim 16 (depends on 9)

The method of claim 9, wherein the cancer is selected from the group consisting of hepatocellular carcinoma, glioblastoma, pleural mesothelioma, differentiated thyroid cancer, advanced renal cell carcinoma, ovarian cancer, breast cancer, pancreatic cancer, lung cancer, colorectal cancer, and combinations thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the cancer is glioblastoma.

### Claim 18 (depends on 9)

The method of claim 9, further defined as a method of reducing a volume of a tumor and/or preventing an increase of volume of the tumor, wherein the tumor is present in a body of a living subject and includes a plurality of cancer cells.

### Claim 19

A system, comprising:
an alternating electric field-generating device; and
at least one composition comprising methylglyoxal.

### Claim 20 (depends on 19)

The system of claim 19, wherein the at least one composition comprises methylglyoxal at a concentration in a range of from about 0.3 mM to about 1 mM.
